Monday January 26, 2026
If there’s a throughline this week, it’s regulatory tailwinds and ecosystem building — FDA/CE clearances are expanding addressable procedure sets while partnerships and M&A tighten the pathway from prototype to scaled manufacturing.
8 things to watch this week:
1. 🧠 What Elekta (OM:EKTA B)’s FDA Nod for AI CT-Linac and New Vice Chair Means For Shareholders
Elekta picked up FDA 510(k) clearance for its AI-enhanced Evo CT-Linac, adding a U.S. commercial catalyst for CT-guided radiation workflows. Pairing that with a board governance update signals a company trying to translate innovation wins into steadier execution and credibility with providers and investors.
Simply Wall St
2. 📈 ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission
ImmunityBio shares jumped after the company said FDA discussions aligned on the path to resubmit ANKTIVA’s sBLA in papillary NMIBC. For device + diagnostics leaders, it’s another reminder that regulatory clarity (even before approval) can rapidly change competitive timelines and partnering leverage around therapy-adjacent tech.
Zacks Investment Research
3. ❤️ Medtronic Advances Cardiology And Diabetes Portfolio With New Approvals And Investment
Medtronic stacked a structural-heart investment (Anteris), EU approval + initial U.S. clinical use for Affera’s Sphere-360 PFA catheter, and FDA clearance for MiniMed Go. Net: continued convergence of electrophysiology, structural heart, and connected diabetes—two of the most competitive “platform” battlegrounds in medtech.
Simply Wall St
4. 🧩 Resonetics acquires Med Ally pulse generator lead manufacturing assets
Resonetics is expanding its bioelectronics/neuromodulation footprint by bringing pulse generator + lead manufacturing assets and know-how in-house. Strategically, it’s about offering more of the AIMD stack—reducing supply chain risk, tightening process IP control, and making Resonetics more “one-stop” for customers pushing toward integrated implant platforms.
The Post and Courier (Berkeley Independent)
5. 🧠 Commercial Decisions Are Far Too Costly for Guessing
Launching, partnering, or fundraising without a defensible view of commercial readiness is one of the fastest ways to destroy value in medtech. RŌG Health works upstream of execution to help leadership teams identify what’s blocking progress and decide, with confidence, what matters next.
Not an agency. Not execution. Decision-grade clarity at inflection points.
6.🤝 Strategic partnership created to support early medical device innovation
Medical Murray and Merge formed a partnership aimed at speeding early-stage innovation (design/prototyping) while creating a cleaner handoff into regulated development and cleanroom manufacturing. This is the playbook we’ll keep seeing: “front-end” innovation studios pairing with downstream manufacturing specialists to shrink time-to-first-real-build without overburdening teams with full QMS too early.
Today’s Medical Developments
7. 🏥 What ACCESS, TEMPO could foreshadow for commercial plans: Angle Health CEO
Angle Health’s CEO argues CMS’s ACCESS model and FDA’s TEMPO pilot could speed real-world evidence generation and shorten the time between adoption, proof, and payment—signals that would ripple into commercial plan expectations. Translation for digital health + device companies: evidence standards may get clearer (and faster), but the bar for ROI and outcomes won’t get lower.
Becker’s Payer Issues
8. 🦾 Intuitive’s da Vinci 5 Secures FDA Cardiac Clearance
Intuitive says FDA cleared da Vinci 5 for use in several cardiac procedures (with a measured rollout), expanding one of the most strategically valuable procedure categories in robotics. The near-term story is training and controlled adoption; the longer-term story is how quickly competitors can answer as cardiac becomes a new proving ground for premium robotic platforms.
MD+DI Online
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items. Interested in becoming a sponsor? Contact us.
Fascinating. It's trully amazing to see how regulatory clarity is accelerating innovation, especially in medical AI. How do you think this pace will impact global health equity in the next decade?